Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced positive response rate results in AML patients with FLT3 (FMS-like tyrosine kinase-3) mutation were presented at the European Hematology …
Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that it is cancelling its Analyst and Investor meeting scheduled for Saturday, June 4, 2016 at 7:00 p.m.
Healthcare analysts are weighing in today on leukemia drug maker Celator Pharmaceuticals Inc (NASDAQ:CPXX) and biotechnology company StemCells Inc (NASDAQ:STEM), as the stocks turned extremely volatile following acquisition …
Celator Pharmaceuticals Inc (NASDAQ:CPXX) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced that they have entered into a definitive agreement for Jazz Pharmaceuticals to acquire Celator …
Celator Pharmaceuticals Inc (NASDAQ:CPXX) is up an overwhelming 71% to $30.12 in pre-market trading following this morning’s announcement that the company will be …
Celator Pharmaceuticals Inc Roth Capital analyst Joseph Pantginis weighs in today on Celator Pharmaceuticals Inc (NASDAQ:CPXX), after the biotech company announced that the FDA granted Breakthrough Therapy …
Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that the United States Food and Drug Administration (FDA) granted Breakthrough Therapy designation to VYXEOS (also known as CPX-351). VYXEOS …
Celator Pharmaceuticals Inc (NASDAQ:CPXX) reported business highlights and financial results for the first quarter ended March 31, 2016. “The first quarter of 2016 was transformative …
Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that patients treated in a Phase 2 clinical study with VYXEOS™ (cytarabine: daunorubicin) Liposome for Injection (also known as …
Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that data for VYXEOS™ (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351), its lead product candidate, will be presented …